Logo image of NEUE

NEUEHEALTH INC (NEUE) Stock Fundamental Analysis

NYSE:NEUE - New York Stock Exchange, Inc. - US10920V4041 - Common Stock - Currency: USD

6.85  0 (0%)

Fundamental Rating

2

NEUE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of NEUE have multiple concerns. NEUE is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NEUE had negative earnings in the past year.
In the past year NEUE has reported a negative cash flow from operations.
NEUE had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NEUE reported negative operating cash flow in multiple years.
NEUE Yearly Net Income VS EBIT VS OCF VS FCFNEUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B -2B -2.5B

1.2 Ratios

NEUE's Return On Assets of -20.31% is on the low side compared to the rest of the industry. NEUE is outperformed by 84.31% of its industry peers.
Industry RankSector Rank
ROA -20.31%
ROE N/A
ROIC N/A
ROA(3y)-54.76%
ROA(5y)-42.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUE Yearly ROA, ROE, ROICNEUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200 300

1.3 Margins

NEUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUE Yearly Profit, Operating, Gross MarginsNEUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

More info and screens

3

2. Health

2.1 Basic Checks

NEUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
NEUE has more shares outstanding than it did 1 year ago.
NEUE has more shares outstanding than it did 5 years ago.
NEUE has a worse debt/assets ratio than last year.
NEUE Yearly Shares OutstandingNEUE Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
NEUE Yearly Total Debt VS Total AssetsNEUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

NEUE has an Altman-Z score of -5.66. This is a bad value and indicates that NEUE is not financially healthy and even has some risk of bankruptcy.
NEUE's Altman-Z score of -5.66 is on the low side compared to the rest of the industry. NEUE is outperformed by 88.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -5.66
ROIC/WACCN/A
WACC6.06%
NEUE Yearly LT Debt VS Equity VS FCFNEUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 1B -1B -2B

2.3 Liquidity

NEUE has a Current Ratio of 3.89. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
NEUE's Current ratio of 3.89 is amongst the best of the industry. NEUE outperforms 89.22% of its industry peers.
NEUE has a Quick Ratio of 3.89. This indicates that NEUE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.89, NEUE belongs to the top of the industry, outperforming 91.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.89
Quick Ratio 3.89
NEUE Yearly Current Assets VS Current LiabilitesNEUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for NEUE have decreased strongly by -529172956216033408.00% in the last year.
Looking at the last year, NEUE shows a very negative growth in Revenue. The Revenue has decreased by -17.91% in the last year.
The Revenue has been growing by 27.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-529172956216033500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.23%
Revenue 1Y (TTM)-17.91%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-11.96%

3.2 Future

The Earnings Per Share is expected to grow by 11.62% on average over the next years. This is quite good.
Based on estimates for the next years, NEUE will show a quite strong growth in Revenue. The Revenue will grow by 16.81% on average per year.
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NEUE Yearly Revenue VS EstimatesNEUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2B 4B 6B
NEUE Yearly EPS VS EstimatesNEUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NEUE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NEUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUE Price Earnings VS Forward Price EarningsNEUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUE Per share dataNEUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.62%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

NEUE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUEHEALTH INC

NYSE:NEUE (6/18/2025, 8:12:27 PM)

6.85

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)08-05 2025-08-05
Inst Owners51.74%
Inst Owner ChangeN/A
Ins Owners12.11%
Ins Owner Change62.25%
Market Cap61.17M
Analysts45.71
Price Target7.14 (4.23%)
Short Float %0.05%
Short Ratio0.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.87%
Min EPS beat(2)74.72%
Max EPS beat(2)111.02%
EPS beat(4)2
Avg EPS beat(4)10.79%
Min EPS beat(4)-118.63%
Max EPS beat(4)111.02%
EPS beat(8)4
Avg EPS beat(8)64.09%
EPS beat(12)5
Avg EPS beat(12)32.51%
EPS beat(16)5
Avg EPS beat(16)-7.43%
Revenue beat(2)0
Avg Revenue beat(2)-21.26%
Min Revenue beat(2)-33.05%
Max Revenue beat(2)-9.47%
Revenue beat(4)0
Avg Revenue beat(4)-14.39%
Min Revenue beat(4)-33.05%
Max Revenue beat(4)-2.77%
Revenue beat(8)1
Avg Revenue beat(8)-8.65%
Revenue beat(12)2
Avg Revenue beat(12)-20.61%
Revenue beat(16)3
Avg Revenue beat(16)-35.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-29.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)18.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)17.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.07
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-11.75
EYN/A
EPS(NY)-14.9
Fwd EYN/A
FCF(TTM)-11.01
FCFYN/A
OCF(TTM)-10.64
OCFYN/A
SpS101.61
BVpS-49.27
TBVpS-57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.76%
ROA(5y)-42.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.01
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.89
Quick Ratio 3.89
Altman-Z -5.66
F-Score4
WACC6.06%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)48.95%
Cap/Sales(3y)0.54%
Cap/Sales(5y)0.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-529172956216033500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.23%
EPS Next Y14%
EPS Next 2Y11.62%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-17.91%
Revenue growth 3Y-14.76%
Revenue growth 5Y27.26%
Sales Q2Q%-11.96%
Revenue Next Year28.84%
Revenue Next 2Y16.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year152.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y88.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y89.02%
OCF growth 3YN/A
OCF growth 5YN/A